Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
7 search results for:

Tisagenlecleucel 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 05-12-2018 | Diffuse large B-cell lymphoma | News | Article

    Durable response to tisagenlecleucel shown in DLBCL

    Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.

    Published in:
    N Engl J Med 2018; doi:10.1056/NEJMoa1804980 ASH 2018; San Diego, California, USA; 1–4 December
  2. 15-05-2018 | FDA | News | Article
    approvalsWatch

    Tisagenlecleucel approved for relapsed, refractory DLBCL

    medwireNews : The US FDA has approved the use of tisagenlecleucel for the treatment of adults with large B-cell lymphoma who have relapsed or refractory disease after at least two lines of systemic chemotherapy.

  3. 13-02-2018 | Acute lymphoblastic leukemia | News | Article

    CAR T-cell therapy promising across age groups in refractory ALL setting

    Specifically, grade 3 or 4 effects related to tisagenlecleucel occurred in 73% of participants, primarily within 8 weeks of infusion, becoming less frequent by 1 year.

    Published in:
    N Engl J Med 2018; 378 : 439–448, 449–459
  4. 22-12-2017 | B-cell lymphoma | News | Article

    CAR T-cell therapy effective for refractory large B-cell lymphomas

    In the second study , 28 patients with relapsed or refractory diffuse large B-cell or follicular lymphoma were treated with the anti-CD19 CAR T-cell therapy CTL019 (tisagenlecleucel) at doses ranging from 1x10 8 to 5x10 8  cells after receiving a lymphodepleting regimen chosen by the investigator on the basis of the patient’s treatment history, blood counts, and organ function.

    Published in:
    N Engl J Med 2017; Advance online publication, ASH 2017; Atlanta, Georgia, USA
  5. 19-10-2017 | CAR T-cell immunotherapy | News | Article
    approvalsWatch

    Second CAR T-cell therapy receives FDA approval

    The decision follows the earlier approval in 2017 of the CAR T-cell immunotherapy tisagenlecleucel for patients with B-cell precursor acute lymphoblastic leukemia who are aged less than 25 years.

  6. 31-08-2017 | Acute lymphoblastic leukemia | News | Article
    approvalsWatch

    CAR T-cell therapy approved for pediatric, young adult B-cell precursor ALL

    medwireNews : Tisagenlecleucel has been granted regular approva l for the treatment of refractory or relapsed B-cell precursor acute lymphoblastic leukemia (ALL) in patients aged up to 25 years by the US FDA.

  7. 16-07-2018 | EMA | News | Article
    approvalsWatch

    EMA recommends two CAR T-cell therapies for approval

    medwireNews : Marketing authorizations have been recommended by the EMA for use of the chimeric antigen receptors (CAR) T-cell therapies tisagenlecleucel and axicabtagene ciloleucel for the treatment of specific blood cancers.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.